Numbers of host 'helper' T cells and proliferating cells predict survival in diffuse small-cell lymphomas

L. J. Medeiros, Louis Picker, A. B. Gelb, J. G. Strickler, S. W. Brain, L. M. Weiss, S. J. Horning, R. A. Warnke

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Diffuse small-cell lymphomas of B-lineage comprise a group of immunophenotypically related lymphoid malignancies that display variable clinical aggressiveness. We compared a variety of clinical, pathologic, and immunologic characteristics of 64 B-lineage diffuse small-cell lymphomas to patient survival in an effort to define prognostically relevant subtypes of these neoplasms. Neither clinical parameters nor histological subclassification correlated with patient outcome. In contrast, three immunologic features of these lymphomas showed a statistically significant relationship with actuarial survival. Neoplasms that manifested ≥ 25% Ki-67+ cells (proliferation-associated antigen), + cells (pan-T antigen), or + cells (helper/inducer T-subset antigen) were associated with significantly decreased patient survival as compared to neoplasms with the reverse phenotype (P = .02, P = .003, P = .0005, respectively). Leu 3 findings were of particular importance in initial biopsies (P = .0007), while the Ki-67 findings were significant regardless of time of biopsy (P = .01 for biopsies at diagnosis and P = .004 for other biopsies). These data indicate that immunologic analysis can demonstrate subsets of diffuse small-cell lymphoma with different biologic potential, and suggest that such analysis be included in the routine work-up of patients with this type of neoplasm.

Original languageEnglish (US)
Pages (from-to)1009-1017
Number of pages9
JournalJournal of Clinical Oncology
Volume7
Issue number8
StatePublished - 1989
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Helper-Inducer T-Lymphocytes
Cell Survival
Biopsy
Neoplasms
Survival
Viral Tumor Antigens
Lymphoma
Cell Proliferation
Phenotype
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Medeiros, L. J., Picker, L., Gelb, A. B., Strickler, J. G., Brain, S. W., Weiss, L. M., ... Warnke, R. A. (1989). Numbers of host 'helper' T cells and proliferating cells predict survival in diffuse small-cell lymphomas. Journal of Clinical Oncology, 7(8), 1009-1017.

Numbers of host 'helper' T cells and proliferating cells predict survival in diffuse small-cell lymphomas. / Medeiros, L. J.; Picker, Louis; Gelb, A. B.; Strickler, J. G.; Brain, S. W.; Weiss, L. M.; Horning, S. J.; Warnke, R. A.

In: Journal of Clinical Oncology, Vol. 7, No. 8, 1989, p. 1009-1017.

Research output: Contribution to journalArticle

Medeiros, LJ, Picker, L, Gelb, AB, Strickler, JG, Brain, SW, Weiss, LM, Horning, SJ & Warnke, RA 1989, 'Numbers of host 'helper' T cells and proliferating cells predict survival in diffuse small-cell lymphomas', Journal of Clinical Oncology, vol. 7, no. 8, pp. 1009-1017.
Medeiros, L. J. ; Picker, Louis ; Gelb, A. B. ; Strickler, J. G. ; Brain, S. W. ; Weiss, L. M. ; Horning, S. J. ; Warnke, R. A. / Numbers of host 'helper' T cells and proliferating cells predict survival in diffuse small-cell lymphomas. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 8. pp. 1009-1017.
@article{e73e0ad731e54d359d88fffdbd831dcc,
title = "Numbers of host 'helper' T cells and proliferating cells predict survival in diffuse small-cell lymphomas",
abstract = "Diffuse small-cell lymphomas of B-lineage comprise a group of immunophenotypically related lymphoid malignancies that display variable clinical aggressiveness. We compared a variety of clinical, pathologic, and immunologic characteristics of 64 B-lineage diffuse small-cell lymphomas to patient survival in an effort to define prognostically relevant subtypes of these neoplasms. Neither clinical parameters nor histological subclassification correlated with patient outcome. In contrast, three immunologic features of these lymphomas showed a statistically significant relationship with actuarial survival. Neoplasms that manifested ≥ 25{\%} Ki-67+ cells (proliferation-associated antigen), + cells (pan-T antigen), or + cells (helper/inducer T-subset antigen) were associated with significantly decreased patient survival as compared to neoplasms with the reverse phenotype (P = .02, P = .003, P = .0005, respectively). Leu 3 findings were of particular importance in initial biopsies (P = .0007), while the Ki-67 findings were significant regardless of time of biopsy (P = .01 for biopsies at diagnosis and P = .004 for other biopsies). These data indicate that immunologic analysis can demonstrate subsets of diffuse small-cell lymphoma with different biologic potential, and suggest that such analysis be included in the routine work-up of patients with this type of neoplasm.",
author = "Medeiros, {L. J.} and Louis Picker and Gelb, {A. B.} and Strickler, {J. G.} and Brain, {S. W.} and Weiss, {L. M.} and Horning, {S. J.} and Warnke, {R. A.}",
year = "1989",
language = "English (US)",
volume = "7",
pages = "1009--1017",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Numbers of host 'helper' T cells and proliferating cells predict survival in diffuse small-cell lymphomas

AU - Medeiros, L. J.

AU - Picker, Louis

AU - Gelb, A. B.

AU - Strickler, J. G.

AU - Brain, S. W.

AU - Weiss, L. M.

AU - Horning, S. J.

AU - Warnke, R. A.

PY - 1989

Y1 - 1989

N2 - Diffuse small-cell lymphomas of B-lineage comprise a group of immunophenotypically related lymphoid malignancies that display variable clinical aggressiveness. We compared a variety of clinical, pathologic, and immunologic characteristics of 64 B-lineage diffuse small-cell lymphomas to patient survival in an effort to define prognostically relevant subtypes of these neoplasms. Neither clinical parameters nor histological subclassification correlated with patient outcome. In contrast, three immunologic features of these lymphomas showed a statistically significant relationship with actuarial survival. Neoplasms that manifested ≥ 25% Ki-67+ cells (proliferation-associated antigen), + cells (pan-T antigen), or + cells (helper/inducer T-subset antigen) were associated with significantly decreased patient survival as compared to neoplasms with the reverse phenotype (P = .02, P = .003, P = .0005, respectively). Leu 3 findings were of particular importance in initial biopsies (P = .0007), while the Ki-67 findings were significant regardless of time of biopsy (P = .01 for biopsies at diagnosis and P = .004 for other biopsies). These data indicate that immunologic analysis can demonstrate subsets of diffuse small-cell lymphoma with different biologic potential, and suggest that such analysis be included in the routine work-up of patients with this type of neoplasm.

AB - Diffuse small-cell lymphomas of B-lineage comprise a group of immunophenotypically related lymphoid malignancies that display variable clinical aggressiveness. We compared a variety of clinical, pathologic, and immunologic characteristics of 64 B-lineage diffuse small-cell lymphomas to patient survival in an effort to define prognostically relevant subtypes of these neoplasms. Neither clinical parameters nor histological subclassification correlated with patient outcome. In contrast, three immunologic features of these lymphomas showed a statistically significant relationship with actuarial survival. Neoplasms that manifested ≥ 25% Ki-67+ cells (proliferation-associated antigen), + cells (pan-T antigen), or + cells (helper/inducer T-subset antigen) were associated with significantly decreased patient survival as compared to neoplasms with the reverse phenotype (P = .02, P = .003, P = .0005, respectively). Leu 3 findings were of particular importance in initial biopsies (P = .0007), while the Ki-67 findings were significant regardless of time of biopsy (P = .01 for biopsies at diagnosis and P = .004 for other biopsies). These data indicate that immunologic analysis can demonstrate subsets of diffuse small-cell lymphoma with different biologic potential, and suggest that such analysis be included in the routine work-up of patients with this type of neoplasm.

UR - http://www.scopus.com/inward/record.url?scp=0024363144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024363144&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1009

EP - 1017

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -